ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
The company is stepping back in second-line breast cancer.
First-in-human study listings include EOS-215 and RO7673396.
The company’s matching strategy for CB-010 will soon be put to the test.
Vobra-duo is discontinued at long last.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
